Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery

Human Gene Therapy Methods

Volumn 25, Issue 4, 2014, Pages 261-268

  Wang, Qizhao ^a   Dong, Biao ^a   Firrman, Jenni ^a   Roberts, Sean ^a   Moore, Andrea Rossi ^a   Cao, Wenjing ^a   Diao, Yong ^b   Kapranov, Philipp ^b   Xu, Ruian ^b   Xiao, Weidong ^a,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUAQIAO UNIVERSITY   (China)

^c Cardiovascular Research Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8; FACTOR VIII ANTIGEN; PARVOVIRUS VECTOR; PLASMID VECTOR; RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR HHC; RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR HLC; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COST; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; GENE EXPRESSION; GENETIC TRANSFECTION; HEAVY CHAIN; HEK293 CELL LINE; HEMOPHILIA A; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN SECRETION; TISSUE CULTURE CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HELPER VIRUS; KNOCKOUT MOUSE; METABOLISM; PROCEDURES; THERAPEUTIC USE;

ANIMALS; DEPENDOVIRUS; FACTOR VIII; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HELPER VIRUSES; HEMOPHILIA A; HUMANS; MICE; MICE, KNOCKOUT; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 84906667355     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2014.093     Document Type: Article

References (41)

1. Bowles, D.E., McPhee, S.W., Li, C., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443-455.
2. Burton, M., Nakai, H., Colosi, P., et al. (1999). Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc. Natl. Acad. Sci. USA 96, 12725-12730.
3. Chao, H., Sun, L., Bruce, A., et al. (2002). Expression of human factor VIII by splicing between dimerized AAV vectors. Mol. Ther. 5, 716-722.
4. Chen, L., Zhu, F., Li, J., et al. (2007). The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol. Ther. 15, 1856-1862.
5. Chen, L., Lu, H., Wang, J., et al. (2009). Enhanced factor VIII heavy chain for gene therapy of hemophilia A. Mol. Ther. 17, 417-424.
6. Dong, B., Nakai, H., and Xiao, W. (2010). Characterization of genome integrity for oversized recombinant AAV vector. Mol. Ther. 18, 87-92.
7. Dong, B., Moore, A.R., Dai, J., et al. (2013). A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy. Nucleic Acids Res. 41, 6609-6617.
8. Duan, D., Yue, Y., and Engelhardt, J.F. (2001). Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4, 383-391.
9. Ferreira, V., Twisk, J., Kwikkers, K.L., et al. (2013). Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of Lipoprotein Lipase deficiency (LPLD) gene therapy. Hum. Gene Ther. 25, 180-188.
10. Gaudet, D., Methot, J., Dery, S., et al. (2013). Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 20, 361-369.
11. Ghosh, A., Yue, Y., and Duan, D. (2006). Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J. Gene Med. 8, 298-305.
12. Ghosh, A., Yue, Y., Lai, Y., and Duan, D. (2008). A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol. Ther. 16, 124-130.
13. Ghosh, A., Yue, Y., and Duan, D. (2011). Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum. Gene Ther. 22, 77-83.
14. Gnatenko, D.V., Saenko, E.L., Jesty, J., et al. (1999). Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. Br. J. Haematol. 104, 27-36.
15. Goncalves, M.A., Van Nierop, G.P., Tijssen, M.R., et al. (2005). High-capacity hybrid viral vector with site-specific integration ability. J. Virol. 79, 3146-3162.
16. Halbert, C.L., Allen, J.M., and Miller, A.D. (2002). Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat. Biotechnol. 20, 697-701.
17. Ishiwata, A., Mimuro, J., Kashiwakura, Y., et al. (2006). Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. Thromb. Res. 118, 627-635.
18. Jiang, H., Pierce, G.F., Ozelo, M.C., et al. (2006). Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. 14, 452-455.
19. Koo, T., Popplewell, L.J., Athanasopoulos, T., and Dickson, G. (2014). Triple trans-splicing AAV vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum. Gene Ther. 25, 98-108.
20. Lai, Y., Yue, Y., Liu, M., et al. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435-1439.
21. Lai, Y., Yue, Y., Liu, M., and Duan, D. (2006). Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors. Hum. Gene Ther. 17, 1036-1042.
22. Lai, Y., Yue, Y., and Duan, D. (2010). Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome or = 8.2 kb. Mol. Ther. 18, 75-79.
23. Lu, H., Chen, L., Wang, J., et al. (2008). Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum. Gene Ther. 19, 648-654.
24. Ma, W., Yu, C., Zhang, W., and Hu, J. (2010). A simple template-dependent ligase ribozyme as the RNA replicase emerging first in the RNA world. Astrobiology 10, 437-447.
25. McIntosh, J., Lenting, P.J., Rosales, C., et al. (2013). Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121, 3335-3344.
26. Miller, N. (2012). Glybera and the future of gene therapy in the European Union. Nat. Rev. Drug Discov. 11, 419.
27. Muramatsu, S., Fujimoto, K., Kato, S., et al. (2010). A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18, 1731-1735.
28. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
29. Ostedgaard, L.S., Rokhlina, T., Karp, P.H., et al. (2005). A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc. Natl. Acad. Sci. USA 102, 2952-2957.
30. Sabatino, D.E., Lange, A.M., Altynova, E.S., et al. (2011). Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol. Ther. 19, 442-449.
31. Sarkar, R., Xiao, W., and Kazazian, H.H., Jr. (2003). A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J. Thromb. Haemost. 1, 220-226.
32. Sarkar, R., Tetreault, R., Gao, G., et al. (2004). Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103, 1253-1260.
33. Scallan, C.D., Liu, T., Parker, A.E., et al. (2003). Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 102, 3919-3926.
34. Scallan, C.D., Jiang, H., Liu, T., et al. (2006). Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107, 1810-1817.
35. Siner, J.I., Iacobelli, N.P., Sabatino, D.E., et al. (2013). Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 121, 4396-4403.
36. Trapani, I., Colella, P., Sommella, A., et al. (2014). Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol. Med. 6, 194-211.
37. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA 97, 13714-13719.
38. Wu, Z., Yang, H., and Colosi, P. (2010). Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80-86.
39. Yan, Z., Zhang, Y., Duan, D., and Engelhardt, J.F. (2000). Transsplicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. USA 97, 6716-6721.
40. Yan, Z., Lei-Butters, D.C., Zhang, Y., et al. (2007). Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum. Gene Ther. 18, 81-87.
41. Yan, Z., Keiser, N.W., Song, Y., et al. (2013). A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia. Mol. Ther. 21, 2181-2194.